ClinicalTrials.gg
RecruitingNCT07241325PWDQ-T2DUpdated Jan 28, 2026

Psychological Well-Being, Depression, and Health-Related Quality of Life in Adults With Type 2 Diabetes: A Cross-Sectional Study

An observational study in Type 2 Diabetes Mellitus (T2DM), Health-related Quality of Life and Depressive Symptoms, sponsored by National Taiwan University Hospital. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-28.

Sponsored by National Taiwan University Hospital · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as recruiting.
  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
500
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Diabetes Mellitus, Type 2 by National Taiwan University Hospital — 9 open to participants now, 9 under way, none of them phase 3. Diabetes Mellitus, Type 2 · National Taiwan University Hospital.

Started
2025
with 1 other
Observational
8 of 17
4 open now
Registered
13th of 17
by date

Among the 17 studies in Diabetes Mellitus, Type 2 by National Taiwan University Hospital, this one is one of 2 that started in 2025, is one of 8 observational ones, and was the 13th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

9 of the 17 studies in Diabetes Mellitus, Type 2 by National Taiwan University Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Diabetes Mellitus, Type 2 by National Taiwan University Hospital, or all of them as a file.
02

Study summary

This prospective cross-sectional observational study aims to explore the relationships among psychological well-being, depression, and quality of life in patients with type 2 diabetes attending the outpatient metabolic clinic at National Taiwan University Hospital. The study will collect data using standardized instruments, including the EQ-5D Health-Related Quality of Life Questionnaire, the PHQ-9 Depression Scale, and the Shalom Scale of Psychological Well-Being, along with demographic and clinical variables such as age, sex, education, body mass index, HbA1c, disease duration, and psychosocial support indicators. Descriptive statistics, Pearson correlation analyses, ANOVA, and multiple linear regression modeling will be performed to identify factors associated with psychological well-being. The findings are expected to provide evidence-based insights to inform tailored interventions and improve the mental health and quality of life of patients with type 2 diabetes.

Read the detailed description

This is a prospective, cross-sectional observational study designed to examine the relationships among psychological well-being, depression, and quality of life in adult patients with type 2 diabetes attending the outpatient metabolic clinic at National Taiwan University Hospital. The study seeks to identify demographic, clinical, and psychosocial factors associated with psychological well-being in this population.

Eligible participants will be ≥18 years old, diagnosed with type 2 diabetes, able to complete self-administered Chinese questionnaires, and willing to provide written informed consent. Patients with major psychiatric disorders, moderate to severe cognitive impairment, acute diabetic complications, or significant communication barriers will be excluded.

Data collection will include demographic variables (e.g., age, sex, education, marital status, religious belief, economic status, family support, sleep quality, exercise habits) and clinical indicators (e.g., diabetes duration, BMI, HbA1c, diabetic complications, estimated glomerular filtration rate). Three standardized instruments will be administered:

EQ-5D-5L to measure health-related quality of life

PHQ-9 to assess depressive symptoms

Shalom Scale to evaluate psychological well-being

The planned sample size is 350 participants. Recruitment will be conducted by the research team during clinic hours. Written informed consent will be obtained before any data collection.

Statistical analyses will include descriptive statistics to summarize participant characteristics and scale scores, Pearson correlation analyses to examine associations between variables, one-way ANOVA to compare psychological well-being across subgroups, and multiple linear regression modeling to identify predictors of psychological well-being.

The study period is from September 2025 to December 2026. This research is investigator-initiated and self-funded. The results will provide an evidence-based foundation for designing tailored clinical and psychosocial interventions to improve mental health and quality of life in patients with type 2 diabetes.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
  • Health-related Quality of Life
  • Depressive Symptoms
  • Psychological Well-being
  • Spiritual Well-being

Keywords

  • Type 2 Diabetes Mellitus
  • Psychological Well-Being
  • Depression
  • PHQ-9
  • EQ-5D-5L
  • Shalom Scale
  • Spiritual Well-Being
  • Psychosocial Support
  • Cross-Sectional
  • Observational
  • Taiwan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients (aged 18 years and older) with a confirmed diagnosis of type 2 diabetes mellitus receiving ongoing outpatient care at the Metabolism Clinic of National Taiwan University Hospital. Approximately 350 participants will be recruited using convenience sampling during routine clinic visits. All participants must be able to read and understand Chinese questionnaires, complete self-administered forms, and provide written informed consent. The study does not include healthy volunteers or individuals without type 2 diabetes.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 18 years or older with full legal capacity.
  2. Clinically diagnosed with Type 2 Diabetes Mellitus and receiving ongoing outpatient care.
  3. Able to read and understand Chinese questionnaires and complete self-administered forms.
  4. Understand the study purpose and procedures and provide written .

Exclusion criteria

Exclusion Criteria:

  1. Presence of major psychiatric disorders (e.g., schizophrenia, bipolar disorder, major depressive disorder).
  2. Moderate to severe cognitive impairment or dementia, as assessed by the clinical physician, making it impossible to complete the questionnaires.
  3. Currently experiencing acute diabetic complications (e.g., diabetic ketoacidosis, hyperosmolar hyperglycemic state) or hospitalization.
  4. Severe language or other communication barriers preventing expression of consent or understanding of study content.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
500 participants (estimated)
Target follow-up
1 Day
Patient registry
Yes
06

What researchers measure

Primary outcomes

  1. Shalom Scale Total Score (Psychological Well-Being)

    The Shalom Scale for Psychological Well-Being will be used to measure psychological well-being. Higher scores indicate better spiritual/psychological well-being. The total score will be analyzed as a continuous variable.

    Time frame: At enrollment (single outpatient visit; questionnaires completed in approximately 30-40 minutes).

Secondary outcomes

  1. PHQ-9 Total Score (Depression Severity)

    The Patient Health Questionnaire-9 (PHQ-9) will be used to assess the severity of depressive symptoms. Total scores range from 0 to 27, where higher scores indicate more severe depression.

    Time frame: Day 1

  2. EQ-5D-5L Index Score (Health Utility)

    The EQ-5D-5L index score will be used to assess health-related quality of life using the Taiwan value set. Index scores typically range from below 0 (health states worse than death) to 1.0 (full health), with higher scores indicating better health status.

    Time frame: Day 1

  3. EQ-5D-5L Visual Analog Scale (VAS)

    The EQ-5D-5L Visual Analog Scale (VAS) will be used to assess patients' self-rated overall health status. Scores range from 0 (worst imaginable health) to 100 (best imaginable health), with higher scores indicating better perceived health.

    Time frame: Day 1

Other outcomes

  1. Associations Between Demographic/Clinical Variables and Psychological Well-Being

    Associations between psychological well-being and demographic or clinical variables will be examined using correlation and multivariable regression analyses. Pearson correlation (r) will be used to assess bivariate associations between the Shalom Scale total score and PHQ-9 total score, EQ-5D-5L index score, and HbA1c (%). Multiple linear regression analyses will be performed to estimate standardized beta coefficients (β) for predictors of Shalom Scale total score, including age, sex, diabetes duration, BMI, HbA1c, presence of complications, family support, sleep quality, and exercise frequency. Results will be reported as correlation coefficients (r) or standardized β coefficients (unitless).

    Time frame: Day 1

  2. Exploratory Subgroup Analyses of Psychological Well-Being, Depression, and Quality of Life

    Exploratory subgroup analyses will be conducted to examine differences in psychological well-being, depression severity, and health-related quality of life across demographic or clinical subgroups. Subgroups of interest include sex (male vs. female), age group (e.g., \<65 vs. ≥65 years), diabetes duration (short vs. long duration), and presence of diabetes-related complications. Group comparisons will be performed using t-tests or ANOVA as appropriate. Results will be reported as mean differences in scores between subgroups.

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
  • National Taiwan University Hospital - Metabolism
    Taipei, 100229, Taiwan
    Recruiting
08

References and documents

Publications

  • Shalom S., Wang Y.T., Wang C.H., Hu R.Z. (2013). Development and validation of the Shalom Scale for psychological well-being in Chinese populations. Fu Jen Medical Journal, 11(3), 197-204.
  • EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990 Dec;16(3):199-208. doi: 10.1016/0168-8510(90)90421-9. PubMed 10109801 ↗
  • Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13. doi: 10.1046/j.1525-1497.2001.016009606.x. PubMed 11556941 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — De-identified individual participant data that may be shared include questionnaire scores and coded demographic and clinical variables (e.g., age group, sex, diabetes duration, BMI category, HbA1c range, presence of complications). No directly identifiable information (such as names, ID numbers, or contact information) will be included. Data will be stored and shared only under institutional data-sharing agreements, following approval by the National Taiwan University Hospital Research Ethics Committee.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: Beginning 12 months after publication of the main results; available for up to 5 years thereafter.

Access criteria: Qualified researchers may request access by submitting a written proposal and institutional data-sharing agreement to the Principal Investigator. Approval will be required from the National Taiwan University Hospital Research Ethics Committee prior to data release.

Data sharing details ↗ · www.ntuh.gov.tw

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Jun 2026, 9 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 24, 2025
First posted
Nov 21, 2025
StartActual
Sep 19, 2025
Primary completionEst.
Jun 30, 2026
CompletionEst.
Oct 1, 2026
Last update
Jan 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07241325
Responsible party
Sponsor
First posted
Nov 21, 2025
Start date
Sep 19, 2025
Primary completion
Jun 30, 2026 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Jan 28, 2026

Study contacts

YI-CHIEH CHUNG, MSN, RN
Contact
ejchung@gmail.com
+886-2-2312-3456 ext. 65371
Ching-Yuan Wang
principal investigator · National Taiwan University Hospital, Department of Internal Medicine (Metabolism)

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion